Hugo Ford
Hugo Ford
Cambridge University Hospitals
Verified email at
TitleCited byYear
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
HER Ford, A Marshall, JA Bridgewater, T Janowitz, FY Coxon, J Wadsley, ...
The lancet oncology 15 (1), 78-86, 2014
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non–small-cell lung cancer (INVITE): A randomized, phase II study
L Crino, F Cappuzzo, P Zatloukal, M Reck, M Pesek, JC Thompson, ...
Journal of Clinical Oncology 26 (26), 4253-4260, 2008
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis
JMJ Weaver, CS Ross-Innes, N Shannon, AG Lynch, T Forshew, ...
Nature genetics 46 (8), 837, 2014
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer
I Chau, MJ Allen, D Cunningham, AR Norman, G Brown, HER Ford, ...
Journal of Clinical Oncology 22 (8), 1420-1429, 2004
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
M Secrier, X Li, N de Silva, MD Eldridge, G Contino, J Bornschein, ...
Nature genetics 48 (10), 1131, 2016
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed
DC Farrugia, HER Ford, D Cunningham, KD Danenberg, PV Danenberg, ...
Clinical cancer research 9 (2), 792-801, 2003
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations
AL Jackman, R Kimbell, HER Ford
European Journal of Cancer 35, S3-S8, 1999
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
E Andreopoulou, PJ Ross, MER O'brien, HER Ford, K Priest, T Eisen, ...
Annals of oncology 15 (9), 1406-1412, 2004
Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracilá…
HER Ford, F Mitchell, D Cunningham, DC Farrugia, ME Hill, C Rees, ...
Clinical cancer research 8 (1), 103-109, 2002
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery
KE Rollins, CJ Peters, PM Safranek, H Ford, TP Baglin, RH Hardwick
European Journal of Surgical Oncology (EJSO) 37 (12), 1072-1077, 2011
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma
TJ Price, PJ Ross, T Hickish, D Tait, AR Norman, HER Ford, G Middleton, ...
Clinical colorectal cancer 3 (4), 235-242, 2004
The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team
D Brighton, M Wood
Churchill Livingstone, 2005
COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.
H Ford, A Marshall, J Wadsley, FY Coxon, W Mansoor, JA Bridgewater, ...
Journal of Clinical Oncology 31 (4_suppl), LBA4-LBA4, 2013
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
T Janowitz, P Thuss-Patience, A Marshall, JH Kang, C Connell, N Cook, ...
British journal of cancer 114 (4), 381, 2016
B3-04: Gefitinib (IRESSA) versus vinorelbine in chemona´ve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study
L Crin˛, P Zatloukal, M Reck, M Pesek, J Thomson, H Ford, F Hirsch, ...
Journal of Thoracic Oncology 2 (8), S341, 2007
Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma
HER Ford, D Cunningham, PJ Ross, S Rao, GW Aherne, TS Benepal, ...
British journal of cancer 83 (2), 146, 2000
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
N De Silva, L Schulz, A Paterson, W Qain, M Secrier, E Godfrey, H Cheow, ...
British journal of cancer 113 (9), 1305, 2015
Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma.
N Cook, A Marshall, JM Blazeby, JA Bridgewater, J Wadsley, FY Coxon, ...
Journal of Clinical Oncology 31 (15_suppl), 4023-4023, 2013
A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer
HER Ford, YS Yap, DW Miles, A Makris, M Hall, L Miller, M Harries, ...
Cancer chemotherapy and pharmacology 58 (6), 809-815, 2006
Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control
CL Harper-Wynne, K Sumpter, C Ryan, K Priest, A Norton, P Ross, ...
Lung Cancer 47 (2), 289-290, 2005
The system can't perform the operation now. Try again later.
Articles 1–20